Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the company’s…
Arrowhead Pharma Reports Pauses Its ARO-ENaC Phase 1/2 Trial
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase 1/2 clinical study
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company's investigational RNA interference (RNAi)
Arrowhead Pharma Early Saturday Highlighted Presentation Of Added Interim 48-Week Liver Biopsy Results From Ongoing Study For Its Investigational RNA Interference Therapeutic Being Co-Developed With Takeda
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the
Arrowhead Highlights Presentation Of Preclinical Data On ARO-DUX4 At FSHD Society International Research Congress
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented preclinical data on the development of ARO-DUX4, the company's investigational RNA interference (RNAi) therapeutic being developed as a treatment for
The Daily Biotech Pulse: Lilly Spikes On Alzheimer’s Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
Stocks That Hit 52-Week Highs On Wednesday
This morning 122 companies reached new 52-week highs.
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today presented positive interim results from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi)
Horizon Acquires Rights to Arrowhead’s RNAi-Based Gout Treatment Candidate
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) and Horizon Therapeutics plc (NASDAQ:HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout.…